Vycor Medical (VYCO) Common Equity (2010 - 2026)

Vycor Medical (VYCO) has reported Common Equity for 17 consecutive years, with -$4.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 9.94% year-over-year to -$4.3 million in Q2 2026; TTM through Jun 2026 was -$4.3 million, a 9.94% decrease from a year earlier, with the FY2025 full-year figure at -$4.1 million, down 10.75% from the prior year.
• Common Equity was -$4.3 million for Q2 2026 at Vycor Medical, down from -$4.2 million in the prior quarter.
• Over five years, Common Equity peaked at -$2.6 million in Q1 2022 and troughed at -$4.3 million in Q2 2026.
• A 5-year average of -$3.5 million and a median of -$3.5 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 222.78% in 2022 and retreated 8.69% in 2026, its largest moves.
• Over 5 years, Common Equity stood at -$2.9 million in 2022, then retreated by 13.08% to -$3.3 million in 2023, then fell by 10.96% to -$3.7 million in 2024, then retreated by 10.75% to -$4.1 million in 2025, then retreated by 4.02% to -$4.3 million in 2026.
• The last three Common Equity figures came in at -$4.3 million (Q2 2026), -$4.2 million (Q1 2026), and -$4.1 million (Q4 2025), per Business Quant data.